A feasibility study of photoacoustic imaging of ex vivo endoscopic mucosal resection tissues from Barrett’s esophagus patients

Authors
Liang Lim1, Catherine J. Streutker2, Norman Marcon2, Maria Cirocco2, Alexandra Lao2, Vladimir V. Iakovlev2, Ralph DaCosta1, Brian C. Wilson1

Institutions
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 St. Michael’s Hospital, Toronto, Ontario, Canada

accepted after revision 2.5.2017

Bibliography

Corresponding author
Liang Lim, PhD, University Health Network – Princess Margaret Cancer Centre, 101 College Street, PMCRT #15-301V Toronto, Ontario M5G 1L7, Canada samlim@utexas.edu

ABSTRACT

Background and study aims Accurate endoscopic detection of dysplasia in patients with Barrett’s esophagus (BE) remains a major clinical challenge. The current standard is to take multiple biopsies under endoscopic image guidance, but this leaves the majority of the tissue unsampled, leading to significant risk of missing dysplasia. Furthermore, determining whether there is submucosal invasion is essential for proper staging. Hence, there is a clinical need for a rapid in vivo wide-field imaging method to identify dysplasia in BE, with the capability of imaging beyond the mucosal layer. We conducted an ex vivo feasibility study using photoacoustic imaging (PAI) in patients undergoing endoscopic mucosal resection (EMR) for known dysplasia. The objective was to characterize the esophageal microvascular pattern, with the long-term goal of performing in vivo endoscopic PAI for dysplasia detection and therapeutic guidance.

Materials and methods EMR tissues were mounted luminal side up. The tissues were scanned over a field of view of 14 mm (width) by 15 mm (depth) at 680, 750, and 850 nm (40 MHz acoustic central frequency). Ultrasound and photoacoustic images were simultaneously acquired. Tissues were then sliced and fixed in formalin for histopathology with hematoxylin and eosin staining. A total of 13 EMR specimens from eight patients were included in the analysis, which consisted of co-registration of the photoacoustic images with corresponding pathologist-classified histological images. We conducted mean difference test of the total hemoglobin distribution between tissue classes.

Results Dysplastic and nondysplastic BE can be distinguished from squamous tissue in 84 % of region-of-interest comparisons (42/50). However, the ability of intrinsic PAI to distinguish dysplasia from NDBE, which is the clinically important challenge, was only about 33 % (10/30).

Conclusion We demonstrated the technical feasibility of this approach. Based on our ex vivo data, changes in total hemoglobin content from intrinsic PAI (i.e. without exogenous contrast) can differentiate BE from squamous esophageal mucosa. However, most likely intrinsic PAI is unable to differentiate dysplastic from nondysplastic BE with adequate sensitivity for clinical translation.

Introduction
In North America approximately 19 000 new cases of esophageal cancer are diagnosed annually. The 5-year survival rate is only about 15 %, with 18 000 cancer-related deaths annually [1, 2]. The most important risk factor for esophageal adenocarcinoma is Barrett’s esophagus (BE), which affects some 3.5 mil-
The current clinical standard for esophageal cancer diagnosis in patients with BE is targeted biopsies of focal visible abnormalities followed by 4-quadrant random biopsy every 1–2 cm along the length of the Barrett’s segment under white-light endoscopic guidance. However, the majority of the tissue remains unsampled, leading to significant risk of missing dysplasia, especially in areas with no visible abnormalities. Biopsied BE tissue is then staged by histopathology: in order of cancer progression, from nondysplastic BE (NDBE), to low grade dysplasia (LGD), high grade dysplasia (HGD) and, ultimately, cancer (e.g. adenocarcinoma). Whereas less than 10% of BE patients progress to HGD or cancer, patients with HGD are at considerably increased risk of progressing to cancer [4], with yearly rates of 4%–11.8% [5,6].

Early detection of dysplasia, especially HGD, is crucial in managing these patients. Newer methodologies such as cytology from brushes [7] and sponges [8] are being developed but are not yet in common usage. Several clinical trials with a variety of chromoendoscopy have shown promising results [9]. However, chromoendoscopy only enhances the surface features of the tissue and does not provide submucosal information. As well as detecting HGD and intramucosal adenocarcinoma, determining whether there is submucosal invasion is essential for proper staging. Thus, the absence of submucosal invasion indicates that minimally invasive endoscopic mucosal resection (EMR) is potentially curative, whereas its presence indicates the need for esophagectomy, which results in significant mortality as well as detriment to quality of life. Hence, there is an unmet need for a rapid, wide-field endoscopic imaging method to identify dysplasia in BE, with the capability of imaging beyond the mucosal layer.

A wide variety of optical imaging and spectroscopic techniques have been investigated to address this need, including diffuse reflectance spectroscopy [10], tissue autofluorescence [11], contrast-based fluorescence [12], Raman spectroscopy [13], optical coherence tomography [14,15], and narrow-band imaging [16], as well as various combinations of these techniques [17]. However, the clinical need is still largely unmet: for example, optical coherence tomography looks promising in providing large-area scanning at high spatial resolution, but is considerably increased risk of progressing to cancer [4], with yearly rates of 4%–11.8% [5,6].

The mechanistic rationale for using photoacoustic imaging (PAI) in BE is that studies using narrow-band imaging [16] or diffuse reflectance spectroscopy [10] have reported microvascular changes between NDBE and dysplasia, and this is consistent with angiogenesis in tumor progression [18,19]. PAI, based on the detection of acoustic waves generated by local absorption of short (~ns) pulses of laser light, is specifically sensitive to detecting blood vessels in tissue as a result of light absorption by haemoglobin, and is also able to image much deeper into tissue (up to 3.5 cm) [20] than other optical endoscopic imaging techniques [21]. Hence, PAI has the potential to provide imaging of microvasculature from the tissue surface to well below the mucosal layer.

We hypothesize that PAI can detect microvasculature changes between nondysplastic and dysplastic BE. Here, we report a feasibility study using PAI in ex vivo tissues from BE patients with known dysplasia who were undergoing EMR. We have previously reported the technical feasibility of this technique [22], and here we provided analysis from our first group of patients. This analysis consisted of acoustic image co-registration with pathologist-annotated histological images, followed by mean difference comparison between the intrinsic PAI intensity images of the EMR specimen and the pathological classification. Initial results show clearly that intrinsic PAI can differentiate BE from squamous tissue (42/50 = 84%), but is likely not sufficiently sensitive to diagnose dysplasia in BE.

Materials and methods

Photoacoustic system

We used a commercial photoacoustic tomography imaging system (Vevo LAZR Visualsonics, Toronto, Ontario, Canada), which has been described in detail elsewhere [23]. This included an integrated fiberoptic linear-array transducer (L2550, Visualsonics, 40 MHz central acoustic frequency, 256 elements) and a crossed-laser-beam geometry for optical excitation [23]. Photoacoustic and ultrasound images were collected at a frame rate of 5 Hz. The linear transducer generated images with a field of view of approximately 15 mm (depth) by 14 mm (width). The PAI system was located adjacent to a clinical endoscopy suite, so that tissue specimens could be imaged immediately after endoscopic resection.

Patient enrollment

All patients were scheduled for routine screening, diagnostic, and/or therapeutic endoscopy at the Gastroenterology Clinic, St. Michael’s Hospital, Toronto, Canada. Patients were 18 years or above, able to sign the informed consent, and had known pathology indicative for EMR. We excluded patients with any underlying medical condition contraindicating EMR or who had gastrointestinal (GI) malignancy treated with chemotherapy or radiotherapy within the past 3 years. All patients provided written informed consent prior to their endoscopy procedure. The study was carried out with institutional Research Ethics Board approval.

Eight patients were enrolled in this initial feasibility study, from whom PAI and ultrasound scans were obtained in 13 ex vivo EMR tissue samples. Patients’ pre-EMR diagnosis ranged from inflamed mucosa to intramucosal carcinoma. Patients’ post-EMR diagnosis ranged from NDBE to intramucosal carcinoma. EMRs were directed at areas with field defect most suspicious for disease. Detailed information of pre-EMR diagnosis, endoscopic descriptions, and resected specimen diagnosis are included in the supplementary materials (see S1. Patient List).

EMR tissue preparation

The study neither changed standard endoscopic procedure nor increased risk to the patients, as the ultrasound and PAI scans were performed on excised tissues. We also confirmed that the imaging procedure had no detectable effect on the tissues and did not compromise subsequent clinical histopathology. When BE with suspected dysplasia is identified during endos-
copy, patients may undergo an EMR procedure to excise BE tissues for diagnosis. There are variations of EMR procedures [24]. In the current study, all EMRs were performed using a Duette suction device (Duette; Cook Medical, Bloomington, Indiana, USA), which excises the tissue by suctioning to draw the tissue into the cap, followed by ligation (rubber banding) to a polyp-like shape and resection using an electrosurgical snare.

Data acquisition

Excised tissues were mounted using ultrasound gel onto a plastic dish (#430167; Corning Inc., New York, USA) filled with clear gelatin (5 % weight of 40 mL volume) to minimize acoustic signals from the dish. Digital photographs were taken and included a scale bar. Phosphate buffered saline was then added to the dish to provide good acoustic contact with the transducer and to prevent tissue dehydration. A transducer cover (CIV-Flex 610–637; CIVco, Iowa, USA) was mounted onto the transducer probe to protect the tissue sample and avoid cross contamination. The transducer was lowered in contact with the phosphate buffered saline and the sample was centered on the transducer field of view. Because of the crossed-laser-beam geometry of the PAI fiber bundle attached to the transducer, there is an optimal photoacoustic zone located between 9 and 11 mm in front of the probe face. Hence, we positioned the top surface of the tissue at 9 mm for consistency between samples.

PAI scans were made at each of 680, 750, and 850 nm. Additional measurements were made at 824 and 970 nm in anticipation of future work in which these data will serve as controls in studies of topical biomarker-targeted porphyrin-lipid nanoparticle contrast [25,26]. The transducer was mounted onto a motorized translational stage and scanned over a 3D volume at ~0.06 mm step size. The time for complete data acquisition over a 17 mm scan distance was approximately 5 minutes (~1 minute per wavelength). The PAI laser power was below the ANSI maximum permissible exposure for skin (20–70 mJ/cm² for 680–970 nm) [27], avoiding any tissue heating that might damage the tissue, as confirmed on subsequent histopathology.

Histopathology procedure

Once data acquisition was completed, a pathologist marked the orientation of the specimen for subsequent histopathology and sectioning along the ultrasound/photoacoustic imaging plane. Larger samples were grossly cut into 2 mm thick slabs prior to fine sectioning. Sectioned tissues were assigned a unique identifier and fixed in 10% formalin. The tissues were kept moist with phosphate buffered saline from the time of excision until fixation in formalin. The whole procedure, from excision to placing the tissue in formalin, was completed within 60 minutes to avoid compromising subsequent clinical histopathology.

Data analysis

PAI and ultrasound data were analyzed in Matlab (Mathworks; Natick, Massachusetts, USA). The PAI intensities at 750 nm and 850 nm were used as input to estimate the relative concentrations of oxy-hemoglobin (HbO₂) and deoxy-hemoglobin (Hb) using the corresponding known molar extinction coefficients (ε_HbO₂ and ε_Hb) [23, 28, 29]. The relative total hemoglobin (HbT) was then given by the sum of the relative HbO₂ and Hb values.

A digitized whole-section hematoxylin and eosin-stained slide from each tissue was segmented and color coded by an expert GI pathologist (C.S. and A.L.) according to the following tissue classes: squamous mucosa (blue), inflammation (gray), intestinal metaplasia (IM; green), dysplasia (yellow), and adenocarcinoma (orange). Fig. 1 shows two typical histological images (Fig. 1a,c), overlaid with the color-coded segmentation. The histopathology slices were then co-registered with the closest corresponding ultrasound and photoacoustic image (Fig. 1b,d), and regions of interest (ROIs) for each tissue class were mapped manually onto these acoustic images. PAI with the above probe-tissue geometry was able to detect signal from blood located up to 2 mm beneath the tissue surface.

The ROI comparisons were limited to regions within 9–11 mm from the transducer surface in order to minimize the effect of nonuniform distribution of the excitation light, and regions within the same field of view to minimize the effects of intra- and inter-patient and site heterogeneity in BE, which is known to be high. To make PAI comparison across patients and specimens without accounting for this heterogeneity would be misleading; therefore, histological mapping was done within each histological slice (Fig. 1a,c) and comparisons were made only within the same field of view. Comparisons were made for all possible ROI permutations within each image: for example, the case shown in Fig. 1a,b, these were ROI-IM vs. ROI-SQ1, ROI-IM vs. ROI-SQ2, and ROI-SQ1 vs. ROI-SQ2, but the third comparison was not included in the final analysis as both ROI-SQ1 and ROI-SQ2 belonged to the same diagnostic class (squamous).

Fig. 2 shows an example of comparison between two ROIs from Fig. 1b. Here, ROI-IM (green) had a higher mean relative HbT value than ROI-SQ1 (blue), the difference being statistically significant (Wilcoxon Rank Sum test, P<0.05). We considered ROI-IM to have higher relative HbT than that of ROI-SQ1 when the mean HbT was higher and the difference in their HbT distributions was statistically significant (P<0.05). If these conditions did not hold, then the relative HbT comparison for that ROI pair was considered to be negative.

Results

Fig. 3 shows 3D reconstruction of a complete EMR tissue volume using the acoustic images from a typical EMR tissue. Ultrasound (Fig. 3a) provided structural information, while PAI (Fig. 3b,c) provided complementary information about the distribution of absorbers (i.e. blood) within the tissue.

The ROI comparisons of relative HbT are summarized in Table 1. In general, the relative HbT differences between the subclasses of BE (dysplasia, NDBe with inflammation, and IM) were not consistent. However, relative HbT was higher in BE than in squamous mucosa in the majority of comparisons.

Based on the relative HbT content, NDBe and BE can be distinguished from squamous tissue in 84% of ROI comparisons (42/50). This is not surprising, as the chronic inflammation and resulting mucosal transformation in BE is associated with
increased vascularity, as evidenced by the marked color difference between BE and squamous mucosa visible on white-light endoscopy. However, the ability of intrinsic PAI to distinguish dysplasia from NDBE, which is the clinically important challenge, was only about 33% (10/30), even though the wavelengths used were hemoglobin sensitive so that PAI was expected to pick up alterations in the tissue microvascular density.

Discussion and conclusions

In terms of technical issues in performing these ex vivo PAI scans, as previously mentioned the crossed-laser-beam geometry of the PAI probe resulted in an optimal photoacoustic zone within the field of view located between 9 and 11 mm from the probe surface. This raised challenges in both data acquisition and analysis. For data acquisition, accurate placement of the tissue sample within the field of view is required to acquire consistent PAI signals from the same tissue volume. However, this is difficult to achieve because the EMR tissue ligation results in a domed or polyp-like specimen shape. Furthermore, the sizes of the EMR tissue samples were highly variable, from $<3 \times 3 \times 2$ mm$^3$ up to $10 \times 12 \times 6$ mm$^3$. Given these constraints, the simplest and most reliable solution was to position the top of the tissue at 9 mm. For data analysis, the crossed-beam geometry has higher spatial variation in intensity than a flat-top beam. Even with simpler beam geometry, the relationship of photoacoustic signal to physiologically relevant parameters is complex, and estimating the hemoglobin-related concentrations is not strictly quantitative, as documented in other studies [30–32]. Hence, as an initial analysis without requiring complex inverse modeling, we included only ROIs lying within the optimal (9 – 11 mm) PAI region. We also limited the comparisons to ROIs within the same image, so as to mitigate the effects of inter-site and inter-patient variations [33]. Our sample pool did not include tissue with submucosal invasion. However, we consistently acquired PAI data beyond 2 mm from the tissue surface, which supports the imaging depth potential of PAI. Future studies will include samples with submucosal invasion. We note, however, that we have successfully imaged PAI-active nanoparticles lying below full-thickness ex vivo porcine intestine that was 2 mm thick (data not shown).

As regards the main clinical findings, the successful identification of BE relative to squamous mucosa indicated that the experimental protocol and image analysis used were not techni-
cally flawed. Furthermore, we repeated the comparison analysis using only the intrinsic PAI intensity (detailed in Supplementary Material S2) and this did not substantially change the results. The observations remained consistent at the ROI, slice, sample, and patient levels, indicating that the findings are not patient- or sample-biased (detailed in Supplementary Material S3). We realized our sample size was less than ideal, but it did serve the purposes of this first feasibility study (power and sample size analysis in Supplementary Material S4).

One might have expected the performance of PAI in identifying BE vs. squamous mucosa to be even better, given how distinct BE appears visually on endoscopy. However, there is very high heterogeneity in BE, and not all regions are equally inflamed and hypervascularized. The more important point was the inability, at least in this ex vivo study, to reliably distinguish dysplasia from NDME, which was hypothesized to be possible based on altered microvascularity. However, it should be noted that there is a relatively poor concordance between even expert GI pathologists in identifying dysplasia, particularly low grade, in BE owing to considerable histological overlap between inflammatory/reactive changes and premalignant transformation [34].

A further limitation in interpreting the present results is that the ex vivo PAI data may not translate directly to the in vivo setting, primarily because of blood loss from the EMR tissue sample. Although most of the blood content is preserved by the ligation process, the blood does not necessarily fully fill the full vascular volume and there may be redistribution within the sample. The oxygen saturation (SO2) value was omitted from the analysis to account for probable hypoxia post resection. Douplik et al. reported an algorithm using diffuse reflectance spectroscopy that involved a combination of the HbT and SO2 values [10], so that accessing the SO2 information with in vivo PAI at multiple wavelengths may improve the diagnostic accuracy and, in the best-case scenario, result in clinically useful detection of dysplasia. To this end, we are developing an endo-
Endoscopic PAI system and will use it to conduct an in vivo trial in the near future to confirm or alter the negative conclusion of the present study. A prototype endoscopic PAI instrument has been reported by Yang et al. [30], but to our knowledge the device has been used only in preclinical in vivo models in the esophagus. Even if intrinsic PAI is not adequate for detecting dysplasia, it should still have value in endoscopic staging of disease, because of its imaging depth capability.

Finally, if the intrinsic differences in microvascularity of dysplasia in BE does indeed prevent adequate endoscopic detectability using intrinsic PAI, then photoacoustic contrast agents may be a useful addition. Hence, in parallel, we are investigating the utility of PAI in combination with nontargeted and biomarker-targeted porphyrin-lipid nanoparticles (porphysomes) [25, 26], which may be administered systemically or by topical application to the tissue to minimize cost and potential toxicity.

**Competing interests**

None

**References**


**Table 1** Summary of region-of-interest comparisons of relative total hemoglobin between the subclasses of Barrett’s esophagus.

<table>
<thead>
<tr>
<th>HbT</th>
<th>Dysplasia vs. NDBE</th>
<th>NDME</th>
<th>BE vs Squamous</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dysplasia &gt; Inflammation*</td>
<td>Dysplasia &gt; IM</td>
<td>Inflammation* &gt; IM</td>
</tr>
<tr>
<td>Positive</td>
<td>6</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Negative</td>
<td>12</td>
<td>8</td>
<td>19</td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
<td>12</td>
<td>27</td>
</tr>
</tbody>
</table>

HbT, total hemoglobin; BE, Barrett’s esophagus; NDBE, nondysplastic BE; IM, intestinal metaplasia.

* NDBE with inflammation.

**Acknowledgments**

This work was supported by an Emerging Frontiers grant (#1022) from the Terry Fox Research Institute. The authors also thank Visualsonics Inc. for equipment support.


Supplementary Materials

S1. Patient List

<table>
<thead>
<tr>
<th>Patient ID#</th>
<th>Pre-EMR diagnosis</th>
<th>Endoscopic descriptions</th>
<th>Paris Classification</th>
<th>EMR ID#</th>
<th>EMR diagnosis (Staging – Stolte Classification)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Suspicious for intramucosal carcinoma</td>
<td>Nodular lesion</td>
<td>0-Is</td>
<td>1</td>
<td>Adenocarcinoma (T1M2)</td>
</tr>
<tr>
<td>3</td>
<td>Inflamed mucosa, no IM or dysplasia identified</td>
<td>Nodular GEJ</td>
<td>0-Is</td>
<td>6</td>
<td>NDBE</td>
</tr>
<tr>
<td>4</td>
<td>HGD</td>
<td>Nodular BE</td>
<td>0-Is</td>
<td>1</td>
<td>HGD</td>
</tr>
<tr>
<td>11</td>
<td>Intramucosal carcinoma</td>
<td>Irregular esophageal mucosa</td>
<td>0-IIa</td>
<td>4</td>
<td>LGD</td>
</tr>
<tr>
<td>15</td>
<td>LGD</td>
<td>Post-ablation, area nonepithelia-lized, slightly nodular</td>
<td>0-IIa</td>
<td>1</td>
<td>NDBE</td>
</tr>
<tr>
<td>16</td>
<td>Intramucosal carcinoma</td>
<td>Irregular slightly raised mucosa</td>
<td>0-IIa</td>
<td>1</td>
<td>Adenocarcinoma (T1M2) + HGD</td>
</tr>
<tr>
<td>17</td>
<td>HGD</td>
<td>Slight nodularity and erosion at GEJ</td>
<td>0-IIa; 0-IIc</td>
<td>1</td>
<td>NDBE</td>
</tr>
<tr>
<td>18</td>
<td>HGD</td>
<td>Slightly raised mucosa</td>
<td>0-IIa</td>
<td>1</td>
<td>Adenocarcinoma (T1M4) + HGD</td>
</tr>
</tbody>
</table>

EMR, endoscopic mucosal resection; HGD, high grade dysplasia; LGD, low grade dysplasia; GEJ, gastroesophageal junction; BE, Barrett’s esophagus; IM, intestinal metaplasia; NDBE, nondysplastic Barrett’s esophagus.

S2. PAI Comparison Analysis using PAI intensity

We repeated the region-of-interest (ROI) analysis using the PAI intensity at 680 nm (maximum laser output) as well as at 750 and 850 nm. In the case shown in ▶ Fig. 1a,b and ▶ Fig. 2, we considered the photoacoustic intensity of ROI-1 to be higher than that of ROI-2 (i.e. to have a “positive” score) when 2 or 3 variables have higher mean value and the difference in their frequency distributions is statistically significant ($P < 0.05$). ▶ Table S2 summarizes the corresponding comparisons using all 3 wavelengths. Overall, the findings results did not change significantly from the use of the relative Hb$_T$ values, so that Hb$_T$ adequately represents the collected data.

<table>
<thead>
<tr>
<th>Score</th>
<th>Dys vs. NDBE</th>
<th>NDBE</th>
<th>BE vs. Squ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dys $&gt;$ Infl</td>
<td>Dys $&gt;$ IM</td>
<td>Infl $&gt;$ IM</td>
</tr>
<tr>
<td>Positive</td>
<td>6</td>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Negative</td>
<td>12</td>
<td>8</td>
<td>14</td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
<td>12</td>
<td>27</td>
</tr>
</tbody>
</table>

Dys-dysplasia, NDBE, nondysplastic Barrett’s esophagus; Squ, squamous; Infl, NDBE with inflammation; IM, intestinal metaplasia.
S3. Comparison Level: ROI vs. Slice vs. Sample vs. Patient

We acquired data from at least one tissue sample from each patient. Each sample can have multiple slices, depending on the size. Within each slice, multiple ROI comparisons are possible, depending on the number of permutations between ROIs. One potential problem is then that the results could be biased by a subgroup of tissue samples or patients if these contributed a major fraction of the data. To check this, we carried out the comparison analysis at each of the ROI, tissue slice, tissue sample, and patient levels. At the ROI level, each comparison was counted as an observation. At the tissue slice level, ROI comparisons from the same slice were combined, with the majority of the observations determining the outcome for that slice. At the tissue sample level, observations from all slices from the sample were combined, and at the patient level observations from all the tissue sample(s) were combined. The most important comparisons are summarized in Table S3.

Again, the relative HbT in BE was higher than in squamous esophagus at least 75% of the time at every level, whereas it was not consistent at any level between dysplasia and NDBE.

<table>
<thead>
<tr>
<th>Table S3</th>
<th>Comparison analysis at different levels.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dys vs. NDBE</td>
<td>ROI</td>
</tr>
<tr>
<td>Positive</td>
<td>10</td>
</tr>
<tr>
<td>Negative</td>
<td>20</td>
</tr>
<tr>
<td>Same</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
</tr>
<tr>
<td>BE vs. Squ</td>
<td>Positive</td>
</tr>
<tr>
<td>Negative</td>
<td>8</td>
</tr>
<tr>
<td>Same</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
</tr>
</tbody>
</table>

Dys, dysplasia; NDBE, nondysplastic Barrett’s esophagus; BE, Barrett’s esophagus; Squ, squamous; ROI, region of interest.

S4. Power and Sample Size Analysis

Notwithstanding the small number of patients in this feasibility study, we conducted a power analysis to compare the mean difference between ROIs. With expected 50 observations (at least 50 data points/pixels for each ROI) in each ROI, we have at least 90% power to detect significant difference between the two ROIs. The calculation is based on the assumed effect size (mean difference) at 1 SD. In order to adjust for multiple comparisons, the significance level is set at 0.0005 (0.05/100, as we conducted 107 tests in total).

We also conducted sample size calculation for a future pilot study. If the power for a single sample test is 0.90 as we conducted above, a total sample size of 35 EMR samples can produce a two-sided 95% confidence interval with a width equal to 0.2 (0.80–1.00).